Page last updated: 2024-12-11
au 006
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AU 006: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9823252 |
| SCHEMBL ID | 8073493 |
| MeSH ID | M0300883 |
Synonyms (12)
| Synonym |
|---|
| 1-(2-methylphenyl)-4-((3-hydroxypropyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline |
| 1-propanol, 3-((2,3-dihydro-1-(2-methylphenyl)-6-(trifluoromethoxy)-1h-pyrrolo(3,2-c)quinolin-4-yl)amino)- |
| au 006 |
| au006 |
| unii-z4bf7o6e6e |
| au-006 |
| 220831-12-9 |
| z4bf7o6e6e , |
| SCHEMBL8073493 |
| 1-(2-methylphenyl)-4-[(3-hydroxypropyl)amino]-6-trifluoromethoxy-2,3-dihydropyrrolo[3,2-c]quinoline |
| 3-[[1-(2-methylphenyl)-6-(trifluoromethoxy)-2,3-dihydropyrrolo[3,2-c]quinolin-4-yl]amino]propan-1-ol |
| Q27294981 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Three patients (125 mg cohort) had dose-limiting toxic effects (grade 3 nausea/vomiting, diarrhea)." | ( Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Anak, Ö; Baselga, J; Birle, D; Chen, LC; Hackl, W; Krop, I; Markman, B; Melendez Cuero, M; Mita, M; Shapiro, GI; Siu, L; Stutvoet, S; Tabernero, J, 2012) | 0.38 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "93), Cmax (7." | ( Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. Fitzgerald, JF; Grant, EM; Nicolau, DP; Nightingale, C; Quintiliani, R; Zhong, M, 2001) | 0.31 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine." | ( Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. Fitzgerald, JF; Grant, EM; Nicolau, DP; Nightingale, C; Quintiliani, R; Zhong, M, 2001) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||